

## 1 **BA.4/BA.5 early surge report Austria**

2

3 Alexander Gamisch<sup>a</sup>, Maria Elisabeth Mustafa<sup>a</sup>

4

5 <sup>a</sup>Dr. Mustafa, Dr. Richter Labor für medizinisch-chemische und mikrobiologische Diagnostik  
6 GmbH, Abteilung Molekularbiologie, Strubergasse 20, 5020 Salzburg

7

### 8 **Abstract**

9 More than two years into the COVID-19 pandemic, the emergence of the Omicron subvariants  
10 BA.4 and BA.5 initiated the fifth wave. BA.4/BA.5 share identical spike proteins and are thus  
11 difficult to differentiate using standard diagnostic tests. The true frequency and diversity of the  
12 two variants in Austria is therefore largely unknown. Aim of this report is to take stock about  
13 the frequency and diversity of BA.4 & BA.5 and their subvariants based on whole genome  
14 sequencing (WGS) data as deposited at GISAID database. Results show that most sequenced  
15 cases belong to BA.5 (c. 86 %) rather than BA.4 (c. 14 %) and that most of the global diversity  
16 (24 out of 32 subvariants) of BA.4 and BA.5 in terms of subvariants described is already present  
17 in Austria. However, most cases can be attributed to a few subvariants (e.g. BA.5.1, BE.1.1,  
18 BA.5.3, BA.5.2.1) with high estimated growth advantage over BA.2 (ranging 103 to 159 %) and  
19 may be worth monitoring as the immediate wave unfolds.

20

## 21 **Introduction**

22 At the dawn of 2022, more than two years into the COVID-19 pandemic, the emergence of the  
23 Omicron subvariants BA.4 and BA.5 in South Africa initiated the fifth wave (Tegally et al.  
24 2022, Mohapatra et al. 2022). In Austria BA.4/BA.5 was first detected mid-May (calendar week  
25 15) and became dominant within weeks in combination with rising cases numbers (AGES<sup>1</sup>)  
26 thereby dampen any hope for a “summer break” before autumn. BA.4/BA.5 carry additional  
27 spike mutations (69-70del, L452R, F486V and the wild type amino acid at Q493) than BA.2  
28 and are likely more transmissible than the latter due to immune evasion (Tegally et al. 2022;  
29 Hoteit and Yassine 2022; Hachmann et al. 2022). BA.4/BA.5 are further hardly distinguishable  
30 by PCR based screening tests and partial genome sequencing approaches that commonly target  
31 the spike gene region (cf. O’Toole et al. 2022; ECDC 2022). As a corollary, the true frequency  
32 and diversity of the two variants in Austria is largely unknown. Moreover, at the time of writing  
33 32 more obscure subvariants of BA.4 and BA.5 have already been described<sup>2</sup>. These subvariants  
34 usually represent epidemiological significant clusters with a significant amount of onward  
35 transmission that are defined by at least one unambiguous evolutionary event (viz. mutation;  
36 Rambaut et al. 2020). Most mutations are inconsequential, but some do alter the biological  
37 properties of the virus (e.g. Saito et al. 2022; Tegally et al. 2022; Hoteit and Yassine 2022;  
38 Hachmann et al. 2022). Therefore, it is useful to track the frequency of the  
39 mutations/subvariants when they emerge. Aim of this report is to provide an overview about  
40 the frequency and diversity of BA.4 & BA.5 and their subvariants in Austria based on public  
41 available whole genome sequencing (WGS) data as deposited at GISAID database (Elbe &  
42 Buckland-Merrett 2017). The potential risk of these subvariants in terms of relative growth  
43 advantage versus a BA.2 baseline is assessed.

44

## 45 **Methods**

46 A total of 1199 complete genomes of BA.4 and BA.5 collected in Austria have been  
47 downloaded from GISAID (Elbe & Buckland-Merrett 2017; GISAID accessed on 08.07.22).  
48 Sequences have then been classified to the Pango-nomenclatur system (Rambaut et al. 2020)  
49 using the Nextclade online tool<sup>3</sup> v.2.0.0 (Aksamentov et al. 2021) and the frequencies per  
50 variant over sampling time were recorded. The Nextclade mutation profile was further used to  
51 manually designate novel variants<sup>4</sup> not yet recognized by the software. Finally, the

---

<sup>1</sup> <https://www.ages.at/mensch/krankheit/krankheitserreger-von-a-bis-z/coronavirus#c12422> [accessed 04.07.22]

<sup>2</sup> <https://github.com/cov-lineages/pango-designation> [accessed 04.07.22]

<sup>3</sup> <https://clades.nextstrain.org> [accessed 08.07.22]

<sup>4</sup> <https://www.pango.network/summary-of-designated-omicron-lineages/> [accessed 04.07.22]

52 Covspectrum<sup>5</sup> (Chen et al. 2022) platform was used to query GISAID genomic data for global  
53 variant frequencies and to calculated transmission advantage versus a BA.2 baseline following  
54 Chen et al. (2021). Due to the limited number of Austrian BA.4/BA.5 genomes (n =1199; see  
55 also Tab.1) the relative growth advantage per week (in percentage; 0% means equal growth) in  
56 the timeframe of the last 3 months [2022-04-04 to 2022-07-04] was calculated based on  
57 European genomes.

58

## 59 **Results and Discussion**

### 60 **BA.4 versus BA.5**

61 All BA.4 and BA.5 subvariants exhibit strong relative growth advantage versus BA.2 (ranging  
62 between 21% and 175%; see Tab. 1) on a continental scale. For comparison, the Alpha variant  
63 (B.1.1.7) exhibit a growth advantage of 43–52 % compared to the “Wild type” SARS-CoV 2  
64 strain (Chen et al. 2021). However, growth advantage of BA.4 subvariants is tendentially lower  
65 than those of BA.5 subvariants (Tab.1). Consequently, albeit BA.4 initially was more frequent  
66 in Austria than BA.5 the proportion has shifted in favor of BA.5 in recent weeks (around  
67 calendar week 17) (Fig.1). Now, in concordance with the global trend, the BA.5 variant is  
68 dominant with c. 86 % (1035/1199) compared to BA.4 (c. 14 % (164/1199) in Austria (Fig.1).

69

### 70 **BA.4/BA5 subvariants**

71 From the 32 subvariants of BA.4/BA5 a total of 24 subvariants were already detected in Austria  
72 over the past 12 weeks (calendar week 15 to 26) (Fig.1, Fig.2) likely due to multiple  
73 independent introductions of the different strains. In Austria, the top five most frequently  
74 sequenced subvariants over the whole timeframe are BA.5.1, BE.1.1, BA.5.3, BA.5.2.1 and  
75 BA.5 thereby representing a total of c. 68 % of cumulative cases sequenced. Of those BA.5.1,  
76 BE.1.1 and BA.5.2.1 show signs of sustained growth whereas BA.5.3 apparently peaked in  
77 calendar week 19 and is on decline ever since. The top five subvariants with the highest growth  
78 advantage (ranging between 175 and 151 %) are BA.5.1.2, BE.1, BE.1.1, BA.5.6, BA.5.2.3  
79 whereas three of those (BA.5.6, BA.5.2.3, BA.5.1.2) are only known from a handful of recent  
80 cases in Austria so far (Tab.1, Fig. 3). The variants BE.1.1, BA.5.2.1, BA.5.1 on the other hand  
81 appear to be more successful than their peers when judged by cases numbers and estimated  
82 growth advantages (Tab.1, Fig. 3) and may be worth monitoring as the proximate wave unfolds.

83

84

---

<sup>5</sup> <https://cov-spectrum.org> [accessed 04.07.22]

85 **Acknowledgements**

86 We gratefully acknowledge all data contributors, i.e. the authors and their originating  
87 laboratories responsible for obtaining the specimens, and their submitting laboratories for  
88 generating the genetic sequence and metadata and sharing via GISAID. Following labs  
89 submitted to GISAID: Bergthaler laboratory, CeMM Research Center for Molecular Medicine  
90 of the Austrian Academy of Sciences; Lifebrain Covid Labor GmbH; Dr. Mustafa, Dr. Richter  
91 Labor für medizinisch-chemische und mikrobiologische Diagnostik GmbH, Abteilung  
92 Molekularbiologie; Center for Virology, Medical University of Vienna; Institute of Virology  
93 Department of Hygiene, Microbiology and Public Health at Innsbruck Medical University.

94

95

96

97

98

99 **References**

- 100 Aksamentov, I., Roemer, C., Hodcroft, E. B., & Neher, R. A. (2021). Nextclade: clade  
101 assignment, mutation calling and quality control for viral genomes. *Journal of Open Source*  
102 *Software*, 6(67), 3773.
- 103
- 104 Chen, C., Nadeau, S. A., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P., ... &  
105 Stadler, T. (2021). Quantification of the spread of SARS-CoV-2 variant B. 1.1. 7 in  
106 Switzerland. *Epidemics*, 37, 100480.
- 107
- 108 Chen, C., Nadeau, S., Yared, M., Voinov, P., Xie, N., Roemer, C., & Stadler, T. (2022). CoV-  
109 Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new  
110 variants. *Bioinformatics*, 38(6), 1735-1737.
- 111
- 112 Elbe, S., & Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative  
113 contribution to global health. *Global challenges*, 1(1), 33-46.
- 114
- 115 European Centre for Disease Prevention and Control (ECDC). Implications of the emergence  
116 and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA – 14  
117 June 2022. ECDC: Stockholm; 2022.
- 118
- 119 Hachmann, N. P., Miller, J., Collier, A. R. Y., Ventura, J. D., Yu, J., Rowe, M., ... & Barouch,  
120 D. H. (2022). Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12. 1, BA.  
121 4, and BA. 5. *New England Journal of Medicine*. 387, 86-88.
- 122
- 123 Hoteit, R., & Yassine, H. M. (2022). Biological Properties of SARS-CoV-2 Variants:  
124 Epidemiological Impact and Clinical Consequences. *Vaccines*, 10(6), 919.
- 125
- 126 Mohapatra, R. K., Kandi, V., Sarangi, A. K., Verma, S., Tuli, H. S., Chakraborty, S., ... &  
127 Dhama, K. (2022). The recently emerged BA. 4 and BA. 5 lineages of Omicron and their  
128 global health concerns amid the ongoing wave of COVID-19 pandemic–Correspondence.  
129 *International Journal of Surgery* (London, England), 103, 106698.
- 130

131 O'Toole, Á., Pybus, O. G., Abram, M. E., Kelly, E. J., & Rambaut, A. (2022). Pango lineage  
132 designation and assignment using SARS-CoV-2 spike gene nucleotide sequences. *BMC*  
133 *genomics*, 23(1), 1-13.

134

135 Rambaut, A., Holmes, E. C., O'Toole, Á., Hill, V., McCrone, J. T., Ruis, C., ... & Pybus, O.  
136 G. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic  
137 epidemiology. *Nature microbiology*, 5(11), 1403-1407.

138

139 Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., ... & de  
140 Oliveira, T. (2022). Continued emergence and evolution of Omicron in South Africa: New  
141 BA. 4 and BA. 5 lineages. *medRxiv*.

142


143 Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., ... & Sato, K. (2022).  
144 Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature*,  
145 602(7896), 300-306.

146

147

148 **Figures**

149



150

151 **Figure 1. Omicron subvariants BA.4 and BA.5 genomes over time (calendar weeks) in Austria. A, BA.4 and BA.5 including subvariants over**

152 **time. B, subvariants of BA.4 and BA.5 over time.**

153

154


155

156 **Figure 2. Heatmap of number BA.4 and BA.5 genomes over time (between calendar**  
 157 **week 15 and 26) in Austria**

	calendar week											
	15	16	17	18	19	20	21	22	23	24	25	26
BA.4	0	2	0	2	1	7	2	2	4	16	10	10
BA.4.1	0	0	0	1	1	8	6	0	3	11	5	6
BA.4.1.1	0	0	0	4	3	4	4	0	2	1	0	0
BA.4.1.2	0	12	3	3	0	14	4	1	0	2	1	1
BA.4.2	0	0	0	0	0	0	0	0	0	1	0	0
BA.4.4	1	1	1	0	0	1	0	1	1	0	1	0
BA.5	0	0	0	1	1	0	1	0	44	11	4	16
BA.5.1	0	0	1	2	5	26	48	11	50	68	60	86
BA.5.1.2	0	0	0	0	0	0	0	0	1	0	2	0
BA.5.1.3	0	0	0	0	0	2	2	0	1	1	3	4
BA.5.2	0	0	0	0	0	3	0	1	7	20	21	26
BA.5.2.1	0	0	0	2	0	6	5	2	1	24	28	38
BA.5.2.3	0	0	0	0	0	0	0	0	0	1	1	0
BA.5.3	0	2	2	24	30	19	20	2	7	2	3	1
BA.5.3.1	0	0	0	0	0	1	0	0	0	3	1	1
BA.5.3.2	0	0	1	1	0	1	5	0	0	2	0	1
BA.5.3.3	0	0	0	0	0	0	0	0	0	1	0	1
BA.5.3.4	0	0	0	0	0	0	0	0	0	0	1	0
BA.5.5	0	0	0	0	0	0	1	1	1	2	2	5
BA.5.6	0	0	0	0	0	0	0	1	0	1	0	3
BE.1	0	0	0	3	2	8	8	0	5	8	7	14
BE.1.1	0	0	2	1	0	0	8	1	15	53	46	37
BF.1	0	0	0	0	1	5	2	0	1	8	2	10
BF.3	0	0	0	0	0	0	0	0	0	2	0	0

158  
159





160

161 **Figure 3. Subvariant growth advantage vs. BA.2 and genomes number**

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180 **Tables**

181 **Table 1. BA.4 and BA.5 subvariants, frequency, associated mutations, genome frequency global and in Austria as well as growth advantage**  
 182 **versus BA.2 based on genomic sequencing data.**

Subvariant	Initial predominant countries <sup>a</sup>	Associated mutation(s) <sup>a</sup>	Global <sup>b</sup>	Austria	Current adv. per week (%) <sup>b</sup>	Conf. int. (%) <sup>b</sup>
BA.4	South Africa	parental lineage	26452*	164*	93%	91-95%
BA.4.1	South Africa	T21570G (S:V3G)	16194*	41	84%	82-87%
BA.4.1.1	South Africa and Germany	A23570G (S:I670V)	938	18	76%	69-83%
BA.4.1.2	Austria	C3176T (Orf1a:P971S)	168	41	21%	14-27%
BA.4.1.3	Israel	A2435G (Orf1a:R724G)	122	0	NA	NA
BA.4.1.4	Israel	G25266T (S:C1235F)	320	0	NA	NA
BA.4.2	USA	C5173A (Orf1a:H1636Q)	767	1	107%	84-130%
BA.4.3	Israel	C21365T (Orf1b:P2633L)	169	0	72%	37-106%
BA.4.4	USA	C25708T (Orf3a:L106F)	1491	7	101%	92-111%
BA.4.5	Australia	G22104A (S:G181E)	154	0	NA	NA
BA.5	South Africa	parental lineage	65951*	1035*	112%	111-114%
BA.5.1	Portugal	C29666T (ORF10:L37F)	23037*	357	103%	102-105%
BA.5.1.1	USA	C25672A (Orf3a:L94I)	806	0	NA	NA
BA.5.1.2	Europe	G27214A (Orf6:V5I)	270	3	151%	131-172%
BA.5.1.3	Germany Portugal and Spain	G22427A (S:V289I)	709	13	114%	105-122%
BA.5.2	South Africa, England and USA	A28330G (ORF9b:D16G)	21221*	78	133%	130-136%
BA.5.2.1	South Africa, England and USA	A27038G (ORF5:T172T)	12918	106	125%	122-128%
BA.5.2.2	France, Martinique	G20356A (Orf1b:G2297S)	257	0	85%	74-96%
BA.5.2.3	UK	G625T (Orf1a:K120N)	334	2	175%	154-196%
BF.1	England, Denmark, Spain and Scotland	G21520T (Orf1ab:V7086F) (Orf1b:2685F)	1944*	0	90%	85-94%
BF.1.1	USA	G10835A (Orf1a:V3524I)	191	29	75%	41-109%
BF.2	Denmark	G14398T (Orf1b:V311L)	260	2	122%	106-137%
BF.3	India	C23202T (S:T547I)	137	0	NA	NA
BF.4	England	A22337G (S:T259A)	248	0	134%	115-153%
BA.5.3	Germany and South Africa	C1931A (ORF1ab:Q556K)	10338*	112	105%	103-108%

BA.5.3.1	South Africa, Austria and England	G28681T (N:E136D)	1933	6	150%	145-154%
BA.5.3.2	Germany	G621A (ORF1ab:R119H)	784	11	67%	62-71%
BA.5.3.3	UK	C6843T (Orf1a:S2193F)	369	2	118%	105-130%
BA.5.3.4	Germany	G20718T (Orf1b:M2417I)	267	1	64%	56-71%
BE.1	South Africa, Austria and England	G16935A (ORF1b:M1156I)	7321*	55	154%	149-159%
BE.1.1	Germany	C11750T (Orf1a:L3829F)	3817	163	159%	153-165%
BE.2	Belgium	C2910T (Orf1a:T882I)	110	0	66%	53-80%
BA.5.5	USA	C21789T (S:T76I)	6417	12	142%	127-157%
BA.5.6	USA	C17402T (Orf1b:A1312V)	1831	5	169%	144-194%

183 <sup>a</sup><https://www.pango.network/summary-of-designated-omicron-lineages/> [accessed 04.07.22]

184 <sup>b</sup><https://cov-spectrum.org> [accessed 04.07.22]

185 \*including subvariants

186

187

188

189

190

191

192

193

194

195

196

197

198

199